BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17577624)

  • 1. Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer.
    Yamanaka T; Matsumoto S; Teramukai S; Ishiwata R; Nagai Y; Fukushima M
    Gastric Cancer; 2007; 10(2):129-34. PubMed ID: 17577624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer.
    Nagashima F; Ohtsu A; Yoshida S; Ito K
    Gastric Cancer; 2005; 8(1):6-11. PubMed ID: 15747168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer].
    Ohtsu A
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():52-6. PubMed ID: 16897972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
    Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects.
    Takahashi I; Kakeji Y; Emi Y; Sakurai M; Yonemura Y; Kimura Y; Maehara Y
    Gastric Cancer; 2003; 6 Suppl 1():28-33. PubMed ID: 12775017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey.
    Kawai H; Ohtsu A; Boku N; Hamamoto Y; Nagashima F; Muto M; Sano Y; Mera K; Yano T; Doi T; Yoshida S
    Gastric Cancer; 2003; 6 Suppl 1():19-23. PubMed ID: 12775015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
    N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients.
    Yamanaka T; Matsumoto S; Teramukai S; Ishiwata R; Nagai Y; Fukushima M
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):335-43. PubMed ID: 17922276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
    Koizumi W; Kurihara M; Nakano S; Hasegawa K
    Oncology; 2000 Apr; 58(3):191-7. PubMed ID: 10765119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
    Koizumi W; Akiya T; Sato A; Sakuyama T; Sasaki E; Tomidokoro T; Hamada T; Fujimori M; Kikuchi Y; Shimada K; Mine T; Yamaguchi K; Sasaki T; Kurihara M
    Cancer Chemother Pharmacol; 2010 May; 65(6):1093-9. PubMed ID: 19727730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
    Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
    Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404).
    Imamura H; Kishimoto T; Takiuchi H; Kimura Y; Morimoto T; Imano M; Iijima S; Yamashita K; Maruyama K; Otsuji T; Kurokawa Y; Furukawa H
    J Chemother; 2014 Feb; 26(1):57-61. PubMed ID: 24090674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of gastric cancer in Asia: the missing link.
    Nishida T
    Lancet Oncol; 2009 Nov; 10(11):1027-8. PubMed ID: 19880057
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma.
    Yamanaka T; Matsumoto S; Teramukai S; Ishiwata R; Nagai Y; Fukushima M
    Br J Cancer; 2007 Jul; 97(1):37-42. PubMed ID: 17551497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
    Kudo M; Moriguchi M; Numata K; Hidaka H; Tanaka H; Ikeda M; Kawazoe S; Ohkawa S; Sato Y; Kaneko S; Furuse J; Takeuchi M; Fang X; Date Y; Takeuchi M; Okusaka T
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):407-417. PubMed ID: 28497756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases.
    Fushida S; Fujimura T; Oyama K; Yagi Y; Kinoshita J; Ohta T
    Anticancer Drugs; 2009 Sep; 20(8):752-6. PubMed ID: 19543076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
    Tsushima T; Hironaka S; Boku N; Machida N; Yamazaki K; Yasui H; Taku K; Fukutomi A; Onozawa Y
    Gastric Cancer; 2010 Nov; 13(4):245-50. PubMed ID: 21128060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
    Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
    Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.